A double blind randomized controlled trial to assess efficacy of nutritional therapy for prevention of recurrence of hepatic encephalopathy in patients with cirrhosis
- PMID: 36574769
- DOI: 10.1111/jgh.16096
A double blind randomized controlled trial to assess efficacy of nutritional therapy for prevention of recurrence of hepatic encephalopathy in patients with cirrhosis
Abstract
Background and aim: Overt hepatic encephalopathy (OHE) has high risk of recurrence and is associated with poor survival. The role of nutrition therapy is well documented in cirrhosis, but its efficacy in preventing the recurrence of OHE has not been studied.
Methods: In double blind RCT, we randomly assigned 150 patients with liver cirrhosis, with history of OHE in recent past to receive nutrition therapy (group I) or no nutrition therapy (group II) and followed up for 6 months. The primary efficacy end points were occurrence of breakthrough episodes and time to breakthrough episode of OHE. Secondary end points were OHE related hospitalizations and time to hospitalization involving OHE. Other parameters included anthropometry, changes in serum cytokines (IL-1, IL-6, IL-10, and TNF-α), endotoxin and myostatin.
Results: There was significant reduction in occurrence of breakthrough episodes of OHE in group I [10 vs 36, hazard ratio 0.20; P < 0.001], OHE-related hospitalization [8 vs 24, hazard ratio 0.27; P < 0.001)]. Times to breakthrough episode of OHE and OHE-related hospitalization were longer in group I. At the end of 6 months, inflammatory and anthropometry parameters showed significant improvement in group I compared with worsening of serum albumin, anthropometric parameters, IL-6, IL-10 and TNF-α in group II. At the end of 6 months, ascites (50 vs 66, P = 0.01), gastrointestinal bleed (2 vs 11, P = 0.007), and jaundice (16 vs 41, P < 0.001) were lower in group I.
Conclusions: Treatment with nutrition therapy prevented recurrence of OHE and decreased OHE-related hospitalizations as compared with no nutrition therapy.
Keywords: cirrhosis; hepatic encephalopathy; nutrition.
© 2023 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Comment in
-
Role of nutrition in the management of hepatic encephalopathy: Do we know all?J Gastroenterol Hepatol. 2023 Apr;38(4):664. doi: 10.1111/jgh.16131. Epub 2023 Feb 3. J Gastroenterol Hepatol. 2023. PMID: 36680787 No abstract available.
Similar articles
-
[Retrospective analysis of risk factors of liver cirrhosis combined with overt hepatic encephalopathy: a single -center case-control study].Zhonghua Gan Zang Bing Za Zhi. 2021 Feb 20;29(2):133-136. doi: 10.3760/cma.j.cn501113-20200708-00378. Zhonghua Gan Zang Bing Za Zhi. 2021. PMID: 33685081 Chinese.
-
Development and validation of the AMMON-OHE model to predict risk of overt hepatic encephalopathy occurrence in outpatients with cirrhosis.J Hepatol. 2023 Oct;79(4):967-976. doi: 10.1016/j.jhep.2023.05.022. Epub 2023 Jun 3. J Hepatol. 2023. PMID: 37277075
-
Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis.J Hepatol. 2020 Jun;72(6):1140-1150. doi: 10.1016/j.jhep.2019.12.021. Epub 2020 Jan 15. J Hepatol. 2020. PMID: 31954206
-
Efficacy and safety of albumin infusion for overt hepatic encephalopathy: A systematic review and meta-analysis.Dig Liver Dis. 2021 Jul;53(7):817-823. doi: 10.1016/j.dld.2021.04.030. Epub 2021 May 16. Dig Liver Dis. 2021. PMID: 34011479
-
Handgrip strength stratifies the risk of covert and overt hepatic encephalopathy in patients with cirrhosis.JPEN J Parenter Enteral Nutr. 2022 May;46(4):858-866. doi: 10.1002/jpen.2222. Epub 2021 Aug 23. JPEN J Parenter Enteral Nutr. 2022. PMID: 34287991 Review.
Cited by
-
Prophylaxis of hepatic encephalopathy: current and future drug targets.Hepatol Int. 2024 Aug;18(4):1096-1109. doi: 10.1007/s12072-024-10647-9. Epub 2024 Mar 16. Hepatol Int. 2024. PMID: 38492132 Review.
-
Importance of comprehensive nutritional assessment in predicting survival in cirrhosis.World J Hepatol. 2025 May 27;17(5):106606. doi: 10.4254/wjh.v17.i5.106606. World J Hepatol. 2025. PMID: 40501461 Free PMC article.
-
Hepatic encephalopathy in non-cirrhotic portal hypertension.Metab Brain Dis. 2025 Jan 16;40(1):103. doi: 10.1007/s11011-024-01522-5. Metab Brain Dis. 2025. PMID: 39821852 Review.
References
-
- Nabi E, Thacker LR, Wade JB et al. Diagnosis of covert hepatic encephalopathy without specialized tests. Clin. Gastroenterol. Hepatol. 2014; 12: 1384-1389.
-
- Jepsen P, Ott P, Andersen PK, Sorensen HT, Vilstrup H. Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology 2010; 51: 1675-1682.
-
- Vilstrup H, Amodio P, Bajaj J et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guidelines by the American Association for the Study of the Liver diseases and the European Association for the Study of Liver. J. Hepatol. 2014; 60: 715-735.
-
- Merli M, Giusto M, Gentili F et al. Nutritional status: its influence on the outcome of patients undergoing liver transplantation. Liver Int. 2010; 30: 208-214.
-
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J. Hepatol. 2019; 70: 172-193.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous